- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Highlights From ASH 2023
Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.
EP: 1.Clinical Characteristics Distinguishing CLL and SLL
EP: 2.Quality of Life Impacted By CLL and SLL Diagnosis and Management
EP: 3.Evaluating Current Treatment Landscape of CLL and SLL
EP: 4.Unmet Needs In CLL and SLL Treatment Management
EP: 5.Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management
EP: 6.Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment
EP: 7.Determining Optimal CLL / SLL Therapy: Ibrutinib, Acalabrutinib and Zanubrutinib
EP: 8.Key Highlights From ASH 2023
EP: 9.Economic Burden Associated With BTK Inhibitor Use
EP: 10.Patient Education Driving BTK Inhibitor Treatment Adherence
EP: 11.Optimizing BTKi Treatment Strategies
EP: 12.Key Considerations for Treating Patients Diagnosed With CLL and SLL
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; and Jennifer Woyach, MD.
The group discusses anticipated data on Bruton tyrosine kinase (BTK) inhibitors presented at the 2023 American Society of Hematology (ASH) annual meeting. Dr Jacobs highlights the updated results from the ALPINE trial comparing zanubrutinib to ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). The initial late-breaking results presented at ASH 2022 showed zanubrutinib had an improved safety profile and progression-free survival benefit over ibrutinib. The updated 1-year follow-up data presented at ASH 2023 confirm this progression-free survival difference has been maintained.
Dr Jacobs notes this updated data help reaffirm the efficacy differences seen between the next-generation BTK inhibitors like zanubrutinib and the original BTK inhibitor ibrutinib. ASH provides an opportunity to see the latest clinical trial results with these novel agents and how they may change treatment approaches for diseases like CLL and small lymphocytic lymphoma going forward.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
